摘要
目的观察三七总甙单体成分人参皂苷Rg1和Rb1对肝纤维化的作用。方法用50%四氯化碳致大鼠肝纤维化模型,共35 d,同时给予三七总皂甙单体成分人参皂苷Rg1或Rb1治疗,于第5周时分离肝组织,电镜观察肝组织病理变化,并应用体视学方法计量各组大鼠肝细胞线粒体的体积密度(Vvm)、面积密度(Svm)、比表面(Qm)和面数密度(Nam)。结果人参皂苷Rg1及三七总甙能减轻肝组织胶原的沉积,改善肝纤维化程度,而人参皂苷Rb1不能改善肝纤维化程度;各组大鼠肝细胞线粒体体视学结果比较组间存在差异。结论人参皂苷Rg1具有三七总甙的抗肝纤维化作用,在一些方面甚至超过三七总甙,故可以认为是较理想的防治肝纤维化的药物。人参皂苷Rb1不具有抗肝纤维化的作用,不是三七总甙抗肝纤维化的有效成分。
Objective To investigate the effect of Panax notoginseng saponin monomers Rg1 an Rb1 in inhibiting hepatic fibrosis.Methods A rat model of hepatic fibrosis was established by using 50% CCl4.Rg1 or Rb1 was administered by hypodermical injection.At the end of the treatment,pathological changes of hepatic tissues were observed by a transmission electron microscope.Stereological data of liver cell mitochondria of all groups were collected and analyzed.Results Rg1 and Panax notoginsenosides alleviated deposition of collagen in hepatic tissues and improved hepatic fibrosis,while Rb1 did not exhibit these functions.The stereological data of liver cell mitochondria of all the groups were statistically different.Conclusion Rg1 had antifibrosis effects,and Rg1 was more effective than Panax notoginsenosides in some aspects.Rg1 is the antifibrotic agent among the panaxsaponins.
出处
《山东大学学报(医学版)》
CAS
北大核心
2012年第1期85-88,共4页
Journal of Shandong University:Health Sciences
基金
昆明医学院青年基金(kylc200510)